"FDA Approves 1st Immunotherapy Drug to Treat Breast Cancer" - Linda Johnson
The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer, Tecentriq. This is for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It's to be given with chemotherapy, the standard treatment. Mount Sinai breast cancer specialist Dr. Amy Tiersten in New York called it "tremendously exciting news." In a study of 900 women, the benefits were modest. Those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone.
— Amy Tiersten, MD, Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Oncologist, Breast Cancer Medical Oncology Program, Dubin Breast Center, The Mount Sinai Hospital
Additional coverage: The New York Times; U.S. News & World Report; Business Insider; National Post; Washington Times; FOX Business Network; MedPage Today